Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops
Irwin Naturals Acquires Ketamine Media, Nation’s Leading Platform For Ketamine Clinics
Irwin Naturals Inc. (OTC: IWINF) is expanding its efforts in offering ketamine-assisted therapy to those in need.
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here’s What Scientists Want To Learn
Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines.
Psychedelics Capital Markets: Silo Pharma’s IPO, $5M Common Stock Offering
Developmental-stage biopharma company Silo Pharma Inc. (NASDAQ: SILO) announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at $5.00 per share, to begin trading on NASDAQ on Tuesday, September 27, 2022 under trading symbol “SILO.”
Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings.
Cybin Acquires Exclusive License To Mindset Pharma’s Tryptamine Compounds Family
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. (NYSE AMERICAN: CYBN) signed an agreement with next-gen psychedelics producer Mindset Pharma Inc.
Canadian Psychedelics Firm And Queens College Develop New Transdermal Drug Delivery System
Life and sciences R&D company Biomind Labs Inc.
EXCLUSIVE: Global Psychedelics Company Silo Wellness Acquires Dyscovry Science, Including Access To Its Gov Collaborations
According to information procured exclusively by Benzinga ahead of an official announcement, global psychedelics company Silo Wellness Inc.
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: How Are They Commercialized?
(Part four of a four-part series)